Journal profile · Pharmacology & Pharmacy
Expert Opinion on Therapeutic Patents
ISSN 1354-3776 · eISSN 1744-7674 · Taylor and Francis Ltd. · ENGLAND · Monthly · Founded 1994
Expert Opinion on Therapeutic Patents: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.91; subscription journal; median 126 days to acceptance (97 articles, last 24 months); community-reported acceptance: moderate; 63 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion on Therapeutic Patents is published by Taylor and Francis Ltd. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Intellectual Property and Patents, Diverse Scientific and Economic Studies and Legal Cases and Commentary, together about 26.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Intellectual Property and PatentsBusiness, Management and Accounting10.3%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance9.1%
- Legal Cases and CommentaryMedicine7.5%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology5.3%
- Monoclonal and Polyclonal Antibodies ResearchMedicine4.8%
- Peptidase Inhibition and AnalysisMedicine4.2%
- Cholinesterase and Neurodegenerative DiseasesMedicine4.1%
- Neuropeptides and Animal PhysiologyNeuroscience3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Chemistry, Medicinal | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Chemistry, Medicinal | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Chemistry, Medicinal | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.91LetPub ·
- CiteScore 2026-06
- 8.3LetPub ·
- SJR 2026-06
- 1.1LetPub ·
- SNIP 2026-06
- 1.04LetPub ·
- h-index
- 61LetPub ·
- h-index
- 104OpenAlex ·
- i10-index
- 1,560OpenAlex ·
- 2-year mean citedness
- 5.56OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 3.03%LetPub ·
Volume
- Articles per year
- 65LetPub ·
Articles by year OpenAlex count · 3,992 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 41 | 5 | 29 |
| 2025 | 63 | 11 | 274 |
| 2024 | 85 | 14 | 748 |
| 2023 | 52 | 9 | 762 |
| 2022 | 50 | 5 | 1,021 |
| 2021 | 68 | 12 | 1,999 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
126 daysMedian, submission to acceptance · P25–P75 92 days – 166 days
- Acceptance to online
- median 11 days (97 articles)
- Submission to online
- median 139 days
- Sample
- 97 articles with submission and acceptance dates (132 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1994
- ISSN
- 1354-3776
- Electronic ISSN
- 1744-7674
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Opinion on Therapeutic Patents
What CAS zone is Expert Opinion on Therapeutic Patents in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion on Therapeutic Patents is in Zone 2 of Medicine, and in Zone 2 of the minor category Chemistry, Medicinal / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion on Therapeutic Patents?
The latest impact factor listed by LetPub is 4.91; CiteScore 8.3, h-index 104.
How long does peer review take at Expert Opinion on Therapeutic Patents?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 126 days (interquartile range 92–166 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Opinion on Therapeutic Patents?
According to LetPub and DOAJ records, Expert Opinion on Therapeutic Patents is indexed in SCIE and Scopus.
Is Expert Opinion on Therapeutic Patents open access, and what is the APC?
Expert Opinion on Therapeutic Patents is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .